Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Virax Biolabs Group Limited (VRAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7800-0.0640 (-7.58%)
At close: 03:54PM EST
0.8000 +0.02 (+2.56%)
After hours: 07:58PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8440
Open0.8500
Bid0.7700 x 1200
Ask0.8000 x 800
Day's Range0.7670 - 0.8500
52 Week Range0.5400 - 29.0000
Volume135,262
Avg. Volume1,392,670
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Virax Biolabs Introduces Human Papillomavirus ("HPV") Test Kit

    Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of HPV test kits with shipments anticipated in Q1 of 2023 to markets accepting the CE mark, such as the European Union. The test kit covers 18 different genotypes of HPV, including type 53, which is higher risk and becoming increasingly prevalent. The specialized diagnostic kits can be found by contact

  • PR Newswire

    COVID-19 Rapid Antigen Test Distributed By Virax Biolabs Receives Emergency Use Authorization in the United States

    Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today that their supplier has received an Emergency Use Authorization ("EUA") from the U.S. FDA for their Over-the-Counter COVID-19 Rapid Antigen Test (the "Test"). The Tests are ready for sale in the US by Virax. Additionally, another Point of Care Rapid Antigen test to be distributed by Virax is seeking an ap

  • PR Newswire

    Virax Biolabs Appoints Richard Pallin as the Vice President of In Vitro Diagnostic Sales

    Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the appointment of Richard Pallin as Vice President of In Vitro Diagnostic Sales.

Advertisement
Advertisement